New Bill Would Bar Quick Generics Approval For PTAB Users
Generics and biosimilar drugmakers who challenge brand patents at the Patent Trial and Appeal Board would be effectively closed off from accelerated approval pathways under a bill introduced Wednesday by U.S....To view the full article, register now.
Already a subscriber? Click here to view full article